Related Experiment Video
Updated: Aug 6, 2026
07:06
Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
Published on: December 8, 2014
Dietary FODMAP Manipulation for Exercise-Associated Gastrointestinal Symptoms: Why Symptom Severity Should Guide Our
Rachel Scrivin1,2, Natália Vilela Silva Daniel3, Gary Slater4
1Faculty of Sport and Health, Toi Ohomai Institute of Technology, Tauranga, New Zealand. Rachel.Scrivin@toiohomai.ac.nz.
Sports Medicine (Auckland, N.Z.)
|July 24, 2026
Summary
Athletes experiencing exercise-induced gastrointestinal syndrome (EIGS) can strategically use low-fermentable oligo-, di-, mono-saccharide and polyol (FODMAP) diets. This approach should be individualized based on symptom severity, not a routine default, to manage symptoms without compromising nutrition.
Area of Science:
- Sports Medicine
- Gastroenterology
- Human Physiology
Background:
- Exercise-induced gastrointestinal syndrome (EIGS) encompasses gastrointestinal disruptions during physical activity.
- Exercise-associated gastrointestinal symptoms (Ex-GIS) like bloating and pain can negatively impact athletic performance.
- Low-fermentable oligo-, di-, mono-saccharide and polyol (FODMAP) diets are recognized for managing irritable bowel syndrome symptoms.
Purpose of the Study:
- To evaluate the strategic application of low-FODMAP diets for athletes experiencing Ex-GIS.
- To differentiate between approaches for severe versus mild/infrequent Ex-GIS.
- To emphasize individualized dietary strategies over routine FODMAP restriction.
Main Methods:
- Review of current literature on EIGS and FODMAP diets in athletes.
- Analysis of symptom presentation and potential mechanisms of Ex-GIS.
- Consideration of dietary adequacy and performance implications.
Main Results:
- Short-term low-FODMAP diets may alleviate severe Ex-GIS around critical events.
- Liberal FODMAP intake might support gastrointestinal integrity in athletes with milder symptoms.
- No consistent evidence shows FODMAP manipulation improves athletic performance.
Conclusions:
- FODMAP manipulation for Ex-GIS should be individualized, considering symptom severity and exercise demands.
- Dietary strategies must balance symptom management with nutritional adequacy.
- Avoidance of unnecessary dietary restriction is crucial for overall athlete health.
Related Concept Videos
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
01:30Irritable Bowel Syndrome III: Medical and Nursing Management
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:21Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
01:17Irritable Bowel Syndrome I: Introduction
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...